Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.


Updates from The Motley Fool

Latest updates on Novartis from Fool.com.  The Fool has written over 500 articles on Novartis.
Novartis Takes Aim at Pfizer

Novartis is closing in on the finish line with a new breast cancer drug that, if approved, could ...

3 Reasons To Buy Biogen

Drugs in Biogen's pipeline and top-shelf financials could mean that Biogen's future may not be as...



Stock Performance

View Interactive NVS Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novartis.
Current Price: $80.63
Prev Close: $81.35
Open: $80.86
Bid: $0.00
Ask: $0.00
Day's Range: $80.57 - $81.02
52wk Range: $66.93 - $83.58
Volume: 1,735,434
Avg Vol 2,713,474
Market Cap: $191B
P/E (ttm): 28.59
EPS (ttm): $2.82
Div & Yield: $2.72 (2.9%)

Company Rating

What our community thinks about Novartis.
CAPS Rating 4 out of 5
 
1454 Outperform
45 Underperform
CAPS All Stars
 
366 Outperform
11 Underperform

How do you think Novartis will perform against the market?



You pick for Novartis is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Joseph Jimenez, CEO

82% Approve

Based on 91 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novartis.

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers